Mounjaro and Type 1 Diabetes: What the Evidence Actually Shows

Step 1: Understand what the licence does (and does not) cover

Mounjaro holds two UK marketing authorisations, both issued by the MHRA: one for weight management in adults with a BMI of 30 or above (or 27 with a weight-related condition), and one for type 2 diabetes. Neither covers type 1. That is not an administrative detail; it reflects the fact that Eli Lilly's clinical programme (including the large SURMOUNT and SURPASS trials, which together involved thousands of adults) specifically excluded people with type 1 diabetes. Regulators base their approvals on the populations studied, and when a group is absent from the trials, the safety and dose profile for that group simply cannot be confirmed.

You can read the NHS overview of tirzepatide, which sets out the approved indications plainly, at the NHS tirzepatide medicines page. The British National Formulary also lists the licensed indications clearly for clinicians at the BNF tirzepatide entry. Both confirm type 1 diabetes is not among them.

It is also worth understanding the mechanism. Tirzepatide activates both the GLP-1 and GIP receptors, which work partly through insulin secretion from the pancreatic beta cells. In type 1 diabetes, those beta cells are largely or entirely non-functional. That changes how the medicine acts — and it is one reason researchers cannot simply extrapolate results from type 2 trials. Our broader guide to how Mounjaro works covers the dual-agonist mechanism in more detail.

Step 2: Weigh the specific risks that apply here

The combination of tirzepatide and insulin (which almost everyone with type 1 diabetes uses) introduces risks that are meaningful and not fully quantified. GLP-1 receptor agonists slow gastric emptying, which affects how quickly carbohydrate enters the bloodstream. In people managing insulin doses carefully timed against meals, that unpredictability can cause low blood sugar (hypoglycaemia) more readily.

A more serious concern is diabetic ketoacidosis (DKA). Some research in type 1 populations using GLP-1 medicines has shown an elevated DKA risk, likely because appetite suppression leads to reduced carbohydrate intake while insulin doses stay constant, or because the glucose-lowering effect prompts inappropriate insulin reduction. DKA can develop quickly and become life-threatening. The MHRA monitors GLP-1 medicines closely; the Drug Safety Update index at GOV.UK is the place to check for the latest safety communications on this class of medicines.

None of this means the question is simple. A small number of endocrinologists do use GLP-1 medicines off-label in carefully selected people with type 1 diabetes who also have significant obesity, with very close monitoring. But that is a specialist decision made with full knowledge of someone's insulin regimen, HbA1c, kidney function and much else besides. It is not a decision a general prescriber, or an online pharmacy, can safely make without that context. You may find our more detailed look at Mounjaro in type 1 diabetes useful as further background.

Step 3: Know what can be discussed, and with whom

If you are living with type 1 diabetes and want to explore weight management options, the conversation belongs with your diabetes care team first. Your endocrinologist or diabetologist understands your insulin sensitivity, your hypo history and how your body responds to changes in diet and activity. That knowledge is irreplaceable when evaluating any medicine that interacts with insulin.

You might also ask your GP to check whether you meet the criteria for a referral to a specialist weight management service, where the full range of options (including medicines, psychological support and structured diet programmes) can be assessed together. The NHS England overview of obesity medicines gives a clear picture of how those services work and what they can offer.

For people with type 2 diabetes, a distinct condition with a very different clinical picture, our page covering whether you can take Mounjaro if you have type 2 diabetes explains the relevant considerations in full. The distinction matters, and for a deeper look at how tirzepatide is used in that setting, our dedicated page on Mounjaro for type 2 diabetes sets out the clinical role and licensed use clearly. If you have type 2 diabetes specifically and want a focused answer to whether this treatment is suitable for you, our page on taking Mounjaro with type 2 diabetes walks through exactly that question. There is also a question many people ask about whether weight-loss medicines might affect diabetes progression, our page on Mounjaro and diabetes reversal looks at the evidence on that.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated system) who assesses your health history before any decision is made. If type 1 diabetes features in your medical history, that fact shapes the review. We take the prescribing of prescription-only medicines seriously, and we will not approve treatment where the clinical picture does not support it. If you would like to explore whether any of the weight management treatments we offer might be appropriate for your situation, you are welcome to start a free consultation and let our prescribers assess the full picture. There is no obligation, and the conversation is confidential.